Key result
WHO-prequalified rotavirus vaccines significantly reduced severe rotavirus diarrhoea episodes in infants and children, with Rotarix preventing 93% of cases in low-mortality countries (RR 0.07).
Why the study?
Do WHO-prequalified rotavirus vaccines prevent severe rotavirus diarrhoea and all-cause diarrhoea in children?
Systematic Review (n=228,233)
Do WHO-prequalified rotavirus vaccines prevent severe rotavirus diarrhoea and all-cause diarrhoea in children?
WHO-prequalified rotavirus vaccines are effective at preventing severe rotavirus diarrhoea in children across countries with varying mortality rates.
Answers are grounded in this paper and cite their sources.
WHO-prequalified rotavirus vaccines safely prevent severe diarrhoea in infants; confirms efficacy yet leaves open optimal use in high-mortality settings.
Rotavirus is a common cause of diarrhoea, diarrhoea-related hospital admissions, and diarrhoea-related deaths worldwide. Rotavirus vaccines prequalified by the World Health Organization (WHO) include Rotarix (GlaxoSmithKline), RotaTeq (Merck), and, more recently, Rotasiil (Serum Institute of India Ltd.), and Rotavac (Bharat Biotech Ltd.).
No takes yet. Share an insight, caveat, or question.
Bergman et al. (2021) conducted a systematic review in rotavirus diarrhoea (n=228,233). Rotavirus vaccines (Rotarix, RotaTeq, Rotasiil, Rotavac) vs. Placebo or no intervention was evaluated on Severe cases of rotavirus diarrhoea per 1000 (up to 1 year follow-up, low-mortality countries, Rotarix) (RR 0.07, 95% CI 0.03-0.18). WHO-prequalified rotavirus vaccines significantly reduced severe rotavirus diarrhoea episodes in infants and children, with Rotarix preventing 93% of cases in low-mortality countries (RR 0.07).
Synapse has enriched 10 related papers. Consider them for comparative context: